Literature DB >> 11847286

Structural basis for abrogated binding between staphylococcal enterotoxin A superantigen vaccine and MHC-IIalpha.

Heike I Krupka1, Brent W Segelke, Robert G Ulrich, Sabine Ringhofer, Mark Knapp, Bernhard Rupp.   

Abstract

Staphylococcal enterotoxins (SEs) are superantigenic protein toxins responsible for a number of life-threatening diseases. The X-ray structure of a staphylococcal enterotoxin A (SEA) triple-mutant (L48R, D70R, and Y92A) vaccine reveals a cascade of structural rearrangements located in three loop regions essential for binding the alpha subunit of major histocompatibility complex class II (MHC-II) molecules. A comparison of hypothetical model complexes between SEA and the SEA triple mutant with MHC-II HLA-DR1 clearly shows disruption of key ionic and hydrophobic interactions necessary for forming the complex. Extensive dislocation of the disulfide loop in particular interferes with MHC-IIalpha binding. The triple-mutant structure provides new insights into the loss of superantigenicity and toxicity of an engineered superantigen and provides a basis for further design of enterotoxin vaccines.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11847286      PMCID: PMC2373479          DOI: 10.1110/ps.39702

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  47 in total

1.  Antibiotic resistance. A vancomycin surprise.

Authors:  M S Gilmore; J A Hoch
Journal:  Nature       Date:  1999-06-10       Impact factor: 49.962

2.  Superantigen vaccines: a comparative study of genetically attenuated receptor-binding mutants of staphylococcal enterotoxin A.

Authors:  S Bavari; B Dyas; R G Ulrich
Journal:  J Infect Dis       Date:  1996-08       Impact factor: 5.226

3.  wARP: improvement and extension of crystallographic phases by weighted averaging of multiple-refined dummy atomic models.

Authors:  A Perrakis; T K Sixma; K S Wilson; V S Lamzin
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  1997-07-01

Review 4.  The crisis in antibiotic resistance.

Authors:  H C Neu
Journal:  Science       Date:  1992-08-21       Impact factor: 47.728

5.  Multiple binding sites for bacterial superantigens on soluble class II MHC molecules.

Authors:  H Kozono; D Parker; J White; P Marrack; J Kappler
Journal:  Immunity       Date:  1995-08       Impact factor: 31.745

Review 6.  Enterococci and vancomycin resistance.

Authors:  G L French
Journal:  Clin Infect Dis       Date:  1998-08       Impact factor: 9.079

Review 7.  Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: therapeutic realities and possibilities.

Authors:  M Michel; L Gutmann
Journal:  Lancet       Date:  1997-06-28       Impact factor: 79.321

8.  Solvent content of protein crystals.

Authors:  B W Matthews
Journal:  J Mol Biol       Date:  1968-04-28       Impact factor: 5.469

9.  Protection against Staphylococcus aureus sepsis by vaccination with recombinant staphylococcal enterotoxin A devoid of superantigenicity.

Authors:  I M Nilsson; M Verdrengh; R G Ulrich; S Bavari; A Tarkowski
Journal:  J Infect Dis       Date:  1999-10       Impact factor: 5.226

10.  Residues of the variable region of the T-cell-receptor beta-chain that interact with S. aureus toxin superantigens.

Authors:  Y W Choi; A Herman; D DiGiusto; T Wade; P Marrack; J Kappler
Journal:  Nature       Date:  1990-08-02       Impact factor: 49.962

View more
  2 in total

1.  Persistence of zinc-binding bacterial superantigens at the surface of antigen-presenting cells contributes to the extreme potency of these superantigens as T-cell activators.

Authors:  Dorothy D Pless; Gordon Ruthel; Emily K Reinke; Robert G Ulrich; Sina Bavari
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

2.  Vaccine based on a ubiquitous cysteinyl protease and streptococcal pyrogenic exotoxin A protects against Streptococcus pyogenes sepsis and toxic shock.

Authors:  Robert G Ulrich
Journal:  J Immune Based Ther Vaccines       Date:  2008-10-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.